FOR IMMEDIATE RELEASE

Media Contact:

Ginger Spitzer, Executive Director 312.341.0500

ginger@stopsarcoidosis.org



CHICAGO (March 21, 2013) — The Foundation for Sarcoidosis Research (FSR) is pleased to announce a gift of \$500,000 to launch a new giving level named the Marvin and Harlene Wool Giving Society. The funds from Marvin and Harlene Wool of St. Louis will boost FSR's ability to invest in large collaborative projects strategically designed to push sarcoidosis research forward into uncharted, promising territories.



Marvin and Harlene Wool with FSR Co-Founders Reading and Andrea Wilson

"The Wool family holds deep insight into the need for a comprehensive approach for a breakthrough in sarcoidosis research," Ginger Spitzer, FSR's Executive Director said about the gift. "They recognize that creating collaborations to push public awareness, patient empowerment, and innovative medical research is critical."

FSR BOARD

Andrea Wilson President and Co-Founder

Reading Wilson, Treasurer and Co-Founder Lakeshore Sport & Fitness

Kirk Allen Sloan Valve Company

Anjan Chatterji, MBA, D.D., LL.M Foley & Lardner, LLP

Daniel Culver, DO FCCP Cleveland Clinic

Louie Hondros, MD Rush University Medical Center

Yvonne James Sarcoidosis Foundation of WV. Inc.

Karen Lambros Patient Advocate

Craig Lipset Pfizer, Inc.

McGhee Williams Osse **Burrell Communications**

Susan Pearlstine Pearlstine Family Companies

Leslie Serchuck, MD Children's Hospital of Philadelphia

"As a family committed to pushing toward a cure for sarcoidosis, we are adamant that research becomes more innovative and collaborative. FSR understands that real people's lives depend on rapid advancements in medical research and we are happy to support their efforts," Marvin and Harlene Wool stated.

As the nation's leading nonprofit organization dedicated to finding a cure for sarcoidosis, FSR is unrolling a new model that will support medical research by employing strategic use of capital and collaboration to move promising therapies quickly from the laboratory to the patient. The new model will employ innovative funding structures, effective coalition building, knowledge sharing initiatives, public and private partnerships, and patient engagement.

To carry out this bench to bedside mission, FSR looks forward to utilizing all stakeholders to support high-impact, early-stage projects that could significantly impact the field of sarcoidosis research.

About Sarcoidosis

Sarcoidosis (SAR-COY-DOE-SIS) is a potentially fatal inflammatory disease that can appear in almost any organ in the body. Although the lungs are affected in more than 90% of patients, the disease often attacks the heart, eyes, central nervous system, liver and kidneys. No cause, approved treatments, or cures are known.

About the Foundation for Sarcoidosis Research

Since its establishment in 2000, FSR has funded over \$1 million in sarcoidosis-specific research. For more information about FSR, please visit: www.stopsarcoidosis.org.